Unicycive Therapeutics faces securities class action over oxylanthanum carbonate NDA statements

Unicycive Therapeutics, Inc.

Securities class action filed Sept 3, 2026 in the U.S. District Court for the Northern District of California against Unicycive and certain officers.
Lawsuit alleges federal securities law violations tied to public statements about the new drug application for oxylanthanum carbonate phosphate binder.
The drug targets hyperphosphatemia in chronic kidney disease patients on dialysis; Unicycive calls the claims meritless and vows vigorous defense.
Report signed Sept 28, 2026 by CFO John Townsend; UNCY common stock trades on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.